Vallon Pharmaceuticals, Inc. filed its 10-K on Feb 24, 2023 for the period ending Dec 31, 2022. In this report its auditor, EisnerAmper LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4007 USD | -1.18% | -94.30% | -94.02% |
Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
- Stock Market
- Equities
- GRI Stock
- News GRI BIOPAR
- Vallon Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt